RemeGen Co., Ltd. (OTCMKTS:REGMF – Get Free Report)’s stock price was up 0.4% on Monday . The stock traded as high as $9.54 and last traded at $9.54. 1,009 shares changed hands during trading, a decline of 12% from the average daily volume of 1,143 shares. The stock had previously closed at $9.50.
RemeGen Stock Down 1.4%
The business has a fifty day moving average price of $10.59 and a two-hundred day moving average price of $10.72.
About RemeGen
RemeGen Co, Ltd. is a Shanghai-based biopharmaceutical company focused on the research, development and commercialization of innovative antibody-based therapeutics for oncology and immunology. Since its founding in 2009, RemeGen has built a portfolio of antibody–drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies aimed at addressing a range of solid tumors and immune-related conditions. The company leverages its in-house discovery, engineering and manufacturing capabilities to advance its pipeline from preclinical stages through clinical trials.
RemeGen’s lead product candidate, Disitamab Vedotin (RC48), is a HER2-targeting ADC that has received regulatory approval in China for HER2-positive gastric cancer and urothelial carcinoma.
Featured Articles
- Five stocks we like better than RemeGen
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
- Photronics Is Quietly Becoming a Key Winner From the AI Boom
- Looking Beyond NVIDIA? These 3 AI ETFs Are Beating the Market
- Palantir’s Kool-Aid Moment: The Math Behind Karp’s Forecast
Receive News & Ratings for RemeGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RemeGen and related companies with MarketBeat.com's FREE daily email newsletter.
